| Short Description : | 2019-nCoV Spike S1-C-His protein was developed in hek293 cells using the region Val16-Arg685. For use in research applications. |
| Host: | HEK293 cells |
| Note: | STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Conjugation: | Unconjugated |
| Formulation: | Lyophilised from a 0.22 Mu m filtered solution of PBS, pH 7.4. or Supplied as a 0.22 Mu m filtered solution in PBS, pH 7.4. |
| Storage Instruction: | Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles. |
| Immunoreactivity: | 1.Measured by its binding ability in a functional ELISA. Immobilized Recombinant SARS-CoV-2 Spike S1 at 2 Mu g/mL (100 Mu L/well) can bind Recombinant Human ACE2 with a linear range of 0.5-8.7 ng/mL.|2.Immobilized Human ACE2 on COOH Chip can bind SAR |
| Determination Method: | < 1.0 EU/Mu g of the protein by LAL method. |
| Immunogen: | Recombinant SARS-CoV-2 (2019-nCoV) Spike S1 Protein is produced by HEK293 cells expression system. The target protein is expressed with sequence (Val16-Arg685) of SARS-COV-2 (2019-nCoV) Spike S1 (Accession #YP_009724390.1) fused with a 6×His tag at t |
| Immunogen Region: | Val16-Arg685 |
| Immunogen Sequence: | VNLTTRTQLPPAYTNSFTRG VYYPDKVFRSSVLHSTQDLF LPFFSNVTWFHAIHVSGTNG TKRFDNPVLPFNDGVYFAST EKSNIIRGWIFGTTLDSKTQ SLLIVNNATNVVIKVCEFQF CNDPFLGVYYHKNNKSWMES EFRVYSSANNCTFEYVSQPF LMDLEGKQGNFKNLREFVFK NIDGYFKIYSKHTPINLVRD LPQGFSALEPLVDLPIGINI TRFQTLLALHRSYLTPGDS |
| Background | Recombinant SARS-CoV-2 (2019-nCoV) Spike S1 Protein is produced by HEK293 cells expression system. The target protein is expressed with sequence (Val16-Arg685) of SARS-COV-2 (2019-nCoV) Spike S1 (Accession #YP_009724390.1) fused with a 6×His tag at the C-terminus. |
Information sourced from Uniprot.org
